Long-term (52–78 weeks) treatment with colesevelam HCl added to metformin therapy in type 2 diabetes mellitus patients
Harold E BaysLouisville Metabolic and Atherosclerosis Research Center, Louisville, Kentucky, USAObjective: To evaluate the long-term safety, tolerability, and efficacy of colesevelam HCl (colesevelam) in type 2 diabetes mellitus patients receiving metformin monotherapy or metformin combination thera...
Saved in:
Main Author: | |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2012
|
Subjects: | |
Online Access: | https://doaj.org/article/e3d6a34ccecb4e2cbc0af2f58703c244 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|